Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar;42(2):333-352.
doi: 10.1002/jimd.12041. Epub 2019 Feb 17.

Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry

Martina Huemer  1   2   3 Daria Diodato  4 Diego Martinelli  4 Giorgia Olivieri  4 Henk Blom  5 Florian Gleich  6 Stefan Kölker  6 Viktor Kožich  7 Andrew A Morris  8 Burkhardt Seifert  9 D Sean Froese  1   2 Matthias R Baumgartner  1   2 Carlo Dionisi-Vici  4 EHOD consortiumCarlos Alcalde Martin  10 Martina Baethmann  11 Diana Ballhausen  12 Javier Blasco-Alonso  13 Nikolas Boy  6 Maria Bueno  14 Rosa Burgos Peláez  15 Roberto Cerone  16 Brigitte Chabrol  17 Kimberly A Chapman  18 Maria Luz Couce  19 Ellen Crushell  20 Jaime Dalmau Serra  21 Luisa Diogo  22 Can Ficicioglu  23 Maria Concepcion García Jimenez  24 Maria Teresa García Silva  25 Ana Maria Gaspar  26 Matthias Gautschi  27 Domingo González-Lamuño  28 Sofia Gouveia  19 Stephanie Grünewald  29 Chris Hendriksz  30 Mirian C H Janssen  31 Pavel Jesina  7 Johannes Koch  32 Vassiliki Konstantopoulou  33 Christian Lavigne  34 Allan M Lund  35 Esmeralda G Martins  36 Silvia Meavilla Olivas  37 Karine Mention  38 Fanny Mochel  39 Helen Mundy  40 Elaine Murphy  41 Stephanie Paquay  42 Consuelo Pedrón-Giner  43 Maria Angeles Ruiz Gómez  44 Saikat Santra  45 Manuel Schiff  46 Ida Vanessa Schwartz  47 Sabine Scholl-Bürgi  48 Aude Servais  49 Anastasia Skouma  50 Christel Tran  12 Inmaculada Vives Piñera  51 John Walter  8   52 James Weisfeld-Adams  53
Affiliations

Phenotype, treatment practice and outcome in the cobalamin-dependent remethylation disorders and MTHFR deficiency: Data from the E-HOD registry

Martina Huemer et al. J Inherit Metab Dis. 2019 Mar.

Abstract

Aim: To explore the clinical presentation, course, treatment and impact of early treatment in patients with remethylation disorders from the European Network and Registry for Homocystinurias and Methylation Defects (E-HOD) international web-based registry.

Results: This review comprises 238 patients (cobalamin C defect n = 161; methylenetetrahydrofolate reductase deficiency n = 50; cobalamin G defect n = 11; cobalamin E defect n = 10; cobalamin D defect n = 5; and cobalamin J defect n = 1) from 47 centres for whom the E-HOD registry includes, as a minimum, data on medical history and enrolment visit. The duration of observation was 127 patient years. In 181 clinically diagnosed patients, the median age at presentation was 30 days (range 1 day to 42 years) and the median age at diagnosis was 3.7 months (range 3 days to 56 years). Seventy-five percent of pre-clinically diagnosed patients with cobalamin C disease became symptomatic within the first 15 days of life. Total homocysteine (tHcy), amino acids and urinary methylmalonic acid (MMA) were the most frequently assessed disease markers; confirmatory diagnostics were mainly molecular genetic studies. Remethylation disorders are multisystem diseases dominated by neurological and eye disease and failure to thrive. In this cohort, mortality, thromboembolic, psychiatric and renal disease were rarer than reported elsewhere. Early treatment correlates with lower overall morbidity but is less effective in preventing eye disease and cognitive impairment. The wide variation in treatment hampers the evaluation of particular therapeutic modalities.

Conclusion: Treatment improves the clinical course of remethylation disorders and reduces morbidity, especially if started early, but neurocognitive and eye symptoms are less responsive. Current treatment is highly variable. This study has the inevitable limitations of a retrospective, registry-based design.

PubMed Disclaimer

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources